Clinical trial
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT06121570
Study timeline
Study start (estimated)2023-11-01Date precision: day
Registry last updated2023-11-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Neoplasmsunresolved
Interventions
Sentinel Lymph Node Biopsy (SLNB)PROCEDURE
DoxorubicinDRUG · verified · RxNorm: doxorubicin
EpirubicinDRUG · verified · RxNorm: epirubicin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
FludarabineDRUG · verified · RxNorm: fludarabine
Interleukin-2BIOLOGICAL
Nab-paclitaxelDRUG
Sponsors & collaborators
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06121570 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.